Cancer Biopsy Market by Product Type (Core Needle Biopsy, Fine Needle Aspiration, Surgical Biopsy), Technology (Imaging Guided Biopsy, Manual Freehand Biopsy, Robotic Assisted Biopsy), Application, End User - Global Forecast 2025-2032
Description
The Cancer Biopsy Market was valued at USD 33.48 billion in 2024 and is projected to grow to USD 37.76 billion in 2025, with a CAGR of 12.95%, reaching USD 88.72 billion by 2032.
An authoritative introduction framing how clinical priorities, device innovation, and care pathway changes are redefining contemporary cancer biopsy practice
The clinical and commercial landscape for cancer biopsy is undergoing significant transformation driven by advances in imaging, device ergonomics, procedural pathways, and cross-disciplinary coordination. Early and accurate tissue diagnosis remains central to precision oncology, yet the mechanisms through which biopsies are planned, executed, and integrated with downstream molecular testing are changing rapidly. Clinicians are increasingly prioritizing minimally invasive approaches that preserve tissue integrity for genomic and immunohistochemical analyses, while health systems emphasize procedural efficiency, patient experience, and diagnostic yield.
Concurrently, technology developers are focusing on innovations that reduce procedural variability and expand access outside traditional hospital settings. Imaging modalities and guidance systems are converging with device-level improvements to enable targeted sampling in anatomically complex sites. These trends are influencing capital allocation, training curricula, and procurement strategies across hospitals, ambulatory surgical centers, diagnostic imaging centers, and physician offices. As stakeholders reassess clinical pathways, the interplay between device design, operator skill, and integrated diagnostics will define the next wave of clinical adoption and continuous improvement.
A clear synthesis of the transformative clinical, technological, and operational shifts that are reshaping biopsy workflows and diagnostic decision making
Over the last several years, a set of transformative shifts has accelerated evolution across clinical practice, device engineering, and care delivery for cancer biopsy. First, the move toward precision medicine has elevated the importance of specimen quality, prompting manufacturers and clinical teams to optimize device designs and sampling strategies. Innovations such as vacuum-assisted retrieval and improvements in core needle construction are being paired with advanced imaging guidance to maximize diagnostic yield while minimizing repeat procedures.
Second, procedural migration from inpatient to ambulatory and office-based settings is reshaping workflow demands and procurement decisions. As outpatient venues gain preference for select biopsy procedures, devices must balance portability, sterility protocols, and ease of training. Third, digital integration is enabling richer pre-procedural planning and post-procedural pathology correlation; interoperability between imaging platforms and laboratory information management is improving turnaround times and diagnostic confidence. Finally, workforce considerations and regulatory dynamics are pushing stakeholders to invest in training pathways and standardized protocols that harmonize operator technique and device performance. Together, these shifts foster an environment where clinical utility, operational efficiency, and technological interoperability coalesce to influence adoption trajectories.
A strategic analysis of how recent United States tariff changes have prompted supply chain resilience, manufacturing realignment, and procurement strategy shifts across the biopsy value chain
The introduction of tariffs and trade policy adjustments in the United States in 2025 has had a multifaceted impact on the cancer biopsy ecosystem, affecting manufacturing strategies, supply chain configurations, and procurement practices. Manufacturers that rely on cross-border component sourcing have experienced upward pressure on input costs, prompting re-evaluation of supplier relationships and just-in-time inventory models. In response, several device producers accelerated nearshoring initiatives and renegotiated contracts to preserve margin and ensure regulatory compliance, while others absorbed incremental costs to maintain competitive pricing and continuity of supply.
Healthcare providers and purchasing organizations have adjusted procurement cycles to reflect lead-time volatility, increasingly prioritizing validated local suppliers and longer-term supply agreements. This shift has influenced tender strategies and capital planning, as institutions weigh the trade-offs between unit cost, reliability, and service level agreements. At the same time, the policy environment catalyzed conversations around domestic manufacturing incentives, potential reshoring subsidies, and the need for diversified distribution networks. Regulatory coordination and clarity around tariff classifications became important considerations for vendors seeking to minimize customs-related delays. Overall, the tariffs acted as a catalyst for supply chain resilience measures, prompting manufacturers and health systems to prioritize robustness, traceability, and strategic sourcing over short-term cost optimization.
A comprehensive segmentation-driven insight mapping that connects product types, clinical applications, enabling technologies, and end-user settings to real-world adoption dynamics
A nuanced understanding of market behavior emerges when product, application, technology, and end-user dimensions are considered together. Based on product type the market is studied across Core Needle Biopsy, Fine Needle Aspiration, Surgical Biopsy, and Vacuum-Assisted Biopsy, revealing divergent clinical roles and adoption dynamics; core needle approaches maintain prominence for many solid-organ indications due to specimen size and architecture retention, whereas fine needle aspiration continues to play a role where cytology suffices or when anatomical access is limited. Based on application the market is studied across Breast, Liver, Lung, Prostate, and Thyroid, demonstrating that tissue acquisition strategies are highly organ-specific and driven by lesion accessibility, imaging correlates, and downstream molecular testing needs. Diagnostic pathways for breast and lung, for example, emphasize image-guided sampling to support multimodal treatment planning, while thyroid workflows often balance cytologic and core tissue approaches.
Based on technology the market is studied across Imaging Guided Biopsy, Manual Freehand Biopsy, and Robotic Assisted Biopsy, underscoring a technological continuum from traditional operator-dependent techniques toward systems that enhance targeting precision and reproducibility. Imaging guided approaches have become foundational for complex anatomic sites, whereas robotic-assisted platforms are being adopted selectively for their ability to reduce variability in high-stakes procedures. Based on end user the market is studied across Ambulatory Surgical Centers, Diagnostic Imaging Centers, Hospitals, and Physicians Offices, highlighting that venue of care influences device selection, staffing models, and capital expenditure priorities; ambulatory settings often prioritize compact, easy-to-use systems, while hospitals invest in integrated imaging-device suites and training infrastructures. Together, these intersecting segmentation dimensions shape procurement priorities, clinical training investments, and innovation focus across the ecosystem.
A detailed regional perspective explaining how differing healthcare infrastructures, regulatory regimes, and clinical priorities shape biopsy technology adoption across global markets
Regional variation shapes clinical practice patterns, regulatory approaches, and commercial strategies for biopsy products and services. In the Americas, clinical pathways have been influenced by a concentration of academic centers, advanced interventional radiology networks, and payer-driven considerations that value efficiency and diagnostic yield. These factors favor technologies that demonstrate procedural reproducibility and compatibility with existing imaging ecosystems. In contrast, Europe, Middle East & Africa present a heterogeneous landscape where regulatory frameworks, healthcare infrastructure maturity, and reimbursement models vary significantly across countries; this diversity necessitates adaptable go-to-market strategies, localized clinical validation, and flexible service models to address disparate adoption curves.
Asia-Pacific is characterized by rapid capacity expansion, investment in diagnostic imaging infrastructure, and growing clinical research activity, leading to accelerated uptake of image-guided and minimally invasive techniques in major urban centers. Supply chain considerations, local manufacturing ambitions, and training initiatives also influence regional vendor selection and partnership models. Across regions, differences in procedural settings, clinical guidelines, and capital availability require tailored commercialization approaches, clinical evidence generation, and education programs to bridge gaps between technology capabilities and localized needs, thereby enabling more effective integration into routine care.
A focused industry perspective on how diverse vendor strategies, clinical evidence generation, and strategic partnerships are shaping competitive advantage in biopsy technologies
Competitive dynamics among leading companies are defined by portfolios that blend procedural devices, imaging integration, and post-procedural support services. Market leaders tend to invest heavily in iterative device improvements that enhance tissue yield and operator ergonomics while pursuing partnerships with imaging and digital health vendors to strengthen end-to-end solutions. Mid-sized and emerging firms often concentrate on niche performance differentiators such as single-use convenience, advanced needle metallurgy, or modular guidance systems that reduce training burden. Strategic collaborations between device manufacturers and diagnostic laboratories or pathology service providers are also notable, as they help close the loop between sample acquisition and actionable molecular reporting.
Investment in clinical evidence and training infrastructure remains a core competitive lever; companies that can demonstrate consistent procedural outcomes across multiple institutions enjoy advantages in procurement discussions. Furthermore, service and reimbursement support capabilities are increasingly important, with vendors providing procedural analytics, maintenance programs, and bundled offerings that address total cost of ownership and operational continuity. Intellectual property management and regulatory agility continue to play a role in sustaining differentiation, while active surveillance of regulatory guidance and clinical guideline updates informs product roadmaps and market messaging strategies.
Actionable strategic recommendations for manufacturers, clinical leaders, and procurement teams to drive resilient growth and sustainable clinical impact in biopsy care
Industry leaders should pursue a balanced strategy that aligns product innovation with operational realities and payer expectations. Prioritize investments in technologies that demonstrably improve specimen quality and reduce repeat procedures, while ensuring that device designs accommodate the needs of ambulatory and office-based settings as well as hospitals. Strengthening supplier diversification and contingency inventory policies will mitigate exposure to trade policy shifts and lead-time disruptions. In parallel, cultivate partnerships with imaging platform providers and pathology services to create integrated solutions that streamline pre-procedural planning and post-procedural diagnostic workflows.
Operationalizing these priorities requires enhanced clinician training programs, simulation curricula, and certification pathways to decrease procedural variability and accelerate adoption. Engage payers proactively by generating real-world evidence that links procedural choices to downstream diagnostic accuracy and care utilization. Finally, adopt modular business models that combine capital, disposables, and service contracts to align vendor incentives with provider outcomes and create durable, value-aligned relationships with purchasing stakeholders.
A transparent methodology summary describing evidence sources, expert interviews, triangulation practices, and limitations that underpin the research insights
The research approach combined a structured review of peer-reviewed literature, regulatory filings, clinical guideline updates, proprietary procedural protocols, and targeted qualitative interviews with interventionalists, pathology leaders, procurement specialists, and device engineers. Primary qualitative interviews focused on procedural decision drivers, device performance in real-world settings, training needs, and supplier selection criteria. Secondary research emphasized cross-referencing clinical practice guidelines, device approvals, and publicly available sourcing information to construct a comprehensive view of technology adoption pathways and supply chain dynamics.
Analytical triangulation was applied to reconcile divergent perspectives and validate recurring themes, while sensitivity to regional regulatory and reimbursement differences informed segmentation analyses. Limitations are acknowledged where heterogeneity in clinical reporting or proprietary contracting obscured complete transparency, and such areas were treated conservatively in interpretation. Ethical standards for interview consent and confidentiality were maintained throughout, and findings were synthesized to prioritize actionable insight while preserving methodological rigor and transparency about data provenance.
A concise conclusion synthesizing technological advances, operational shifts, and strategic priorities that will determine long-term biopsy practice evolution
In conclusion, the cancer biopsy landscape is at an inflection point where technological innovation, procedural migration, and supply chain resilience intersect to redefine diagnostic pathways. Improvements in device engineering, integration with advanced imaging, and emphasis on specimen quality are collectively enhancing diagnostic confidence and enabling closer alignment with precision oncology objectives. Simultaneously, evolving care settings and trade policy adjustments are prompting stakeholders to rethink sourcing strategies, training programs, and procurement practices to maintain continuity and optimize clinical outcomes.
Moving forward, the most effective strategies will be those that integrate product innovation with robust clinical evidence generation, targeted education, and adaptive commercial models that reflect venue-of-care differences. Organizations that anticipate regulatory shifts, diversify supply chains, and invest in partnerships across imaging and diagnostic services will be better positioned to deliver sustained value to clinicians, patients, and health systems. The convergence of technological capability and operational insight thus offers a path to more reliable, patient-centered tissue diagnosis and streamlined integration into contemporary oncology care.
Note: PDF & Excel + Online Access - 1 Year
An authoritative introduction framing how clinical priorities, device innovation, and care pathway changes are redefining contemporary cancer biopsy practice
The clinical and commercial landscape for cancer biopsy is undergoing significant transformation driven by advances in imaging, device ergonomics, procedural pathways, and cross-disciplinary coordination. Early and accurate tissue diagnosis remains central to precision oncology, yet the mechanisms through which biopsies are planned, executed, and integrated with downstream molecular testing are changing rapidly. Clinicians are increasingly prioritizing minimally invasive approaches that preserve tissue integrity for genomic and immunohistochemical analyses, while health systems emphasize procedural efficiency, patient experience, and diagnostic yield.
Concurrently, technology developers are focusing on innovations that reduce procedural variability and expand access outside traditional hospital settings. Imaging modalities and guidance systems are converging with device-level improvements to enable targeted sampling in anatomically complex sites. These trends are influencing capital allocation, training curricula, and procurement strategies across hospitals, ambulatory surgical centers, diagnostic imaging centers, and physician offices. As stakeholders reassess clinical pathways, the interplay between device design, operator skill, and integrated diagnostics will define the next wave of clinical adoption and continuous improvement.
A clear synthesis of the transformative clinical, technological, and operational shifts that are reshaping biopsy workflows and diagnostic decision making
Over the last several years, a set of transformative shifts has accelerated evolution across clinical practice, device engineering, and care delivery for cancer biopsy. First, the move toward precision medicine has elevated the importance of specimen quality, prompting manufacturers and clinical teams to optimize device designs and sampling strategies. Innovations such as vacuum-assisted retrieval and improvements in core needle construction are being paired with advanced imaging guidance to maximize diagnostic yield while minimizing repeat procedures.
Second, procedural migration from inpatient to ambulatory and office-based settings is reshaping workflow demands and procurement decisions. As outpatient venues gain preference for select biopsy procedures, devices must balance portability, sterility protocols, and ease of training. Third, digital integration is enabling richer pre-procedural planning and post-procedural pathology correlation; interoperability between imaging platforms and laboratory information management is improving turnaround times and diagnostic confidence. Finally, workforce considerations and regulatory dynamics are pushing stakeholders to invest in training pathways and standardized protocols that harmonize operator technique and device performance. Together, these shifts foster an environment where clinical utility, operational efficiency, and technological interoperability coalesce to influence adoption trajectories.
A strategic analysis of how recent United States tariff changes have prompted supply chain resilience, manufacturing realignment, and procurement strategy shifts across the biopsy value chain
The introduction of tariffs and trade policy adjustments in the United States in 2025 has had a multifaceted impact on the cancer biopsy ecosystem, affecting manufacturing strategies, supply chain configurations, and procurement practices. Manufacturers that rely on cross-border component sourcing have experienced upward pressure on input costs, prompting re-evaluation of supplier relationships and just-in-time inventory models. In response, several device producers accelerated nearshoring initiatives and renegotiated contracts to preserve margin and ensure regulatory compliance, while others absorbed incremental costs to maintain competitive pricing and continuity of supply.
Healthcare providers and purchasing organizations have adjusted procurement cycles to reflect lead-time volatility, increasingly prioritizing validated local suppliers and longer-term supply agreements. This shift has influenced tender strategies and capital planning, as institutions weigh the trade-offs between unit cost, reliability, and service level agreements. At the same time, the policy environment catalyzed conversations around domestic manufacturing incentives, potential reshoring subsidies, and the need for diversified distribution networks. Regulatory coordination and clarity around tariff classifications became important considerations for vendors seeking to minimize customs-related delays. Overall, the tariffs acted as a catalyst for supply chain resilience measures, prompting manufacturers and health systems to prioritize robustness, traceability, and strategic sourcing over short-term cost optimization.
A comprehensive segmentation-driven insight mapping that connects product types, clinical applications, enabling technologies, and end-user settings to real-world adoption dynamics
A nuanced understanding of market behavior emerges when product, application, technology, and end-user dimensions are considered together. Based on product type the market is studied across Core Needle Biopsy, Fine Needle Aspiration, Surgical Biopsy, and Vacuum-Assisted Biopsy, revealing divergent clinical roles and adoption dynamics; core needle approaches maintain prominence for many solid-organ indications due to specimen size and architecture retention, whereas fine needle aspiration continues to play a role where cytology suffices or when anatomical access is limited. Based on application the market is studied across Breast, Liver, Lung, Prostate, and Thyroid, demonstrating that tissue acquisition strategies are highly organ-specific and driven by lesion accessibility, imaging correlates, and downstream molecular testing needs. Diagnostic pathways for breast and lung, for example, emphasize image-guided sampling to support multimodal treatment planning, while thyroid workflows often balance cytologic and core tissue approaches.
Based on technology the market is studied across Imaging Guided Biopsy, Manual Freehand Biopsy, and Robotic Assisted Biopsy, underscoring a technological continuum from traditional operator-dependent techniques toward systems that enhance targeting precision and reproducibility. Imaging guided approaches have become foundational for complex anatomic sites, whereas robotic-assisted platforms are being adopted selectively for their ability to reduce variability in high-stakes procedures. Based on end user the market is studied across Ambulatory Surgical Centers, Diagnostic Imaging Centers, Hospitals, and Physicians Offices, highlighting that venue of care influences device selection, staffing models, and capital expenditure priorities; ambulatory settings often prioritize compact, easy-to-use systems, while hospitals invest in integrated imaging-device suites and training infrastructures. Together, these intersecting segmentation dimensions shape procurement priorities, clinical training investments, and innovation focus across the ecosystem.
A detailed regional perspective explaining how differing healthcare infrastructures, regulatory regimes, and clinical priorities shape biopsy technology adoption across global markets
Regional variation shapes clinical practice patterns, regulatory approaches, and commercial strategies for biopsy products and services. In the Americas, clinical pathways have been influenced by a concentration of academic centers, advanced interventional radiology networks, and payer-driven considerations that value efficiency and diagnostic yield. These factors favor technologies that demonstrate procedural reproducibility and compatibility with existing imaging ecosystems. In contrast, Europe, Middle East & Africa present a heterogeneous landscape where regulatory frameworks, healthcare infrastructure maturity, and reimbursement models vary significantly across countries; this diversity necessitates adaptable go-to-market strategies, localized clinical validation, and flexible service models to address disparate adoption curves.
Asia-Pacific is characterized by rapid capacity expansion, investment in diagnostic imaging infrastructure, and growing clinical research activity, leading to accelerated uptake of image-guided and minimally invasive techniques in major urban centers. Supply chain considerations, local manufacturing ambitions, and training initiatives also influence regional vendor selection and partnership models. Across regions, differences in procedural settings, clinical guidelines, and capital availability require tailored commercialization approaches, clinical evidence generation, and education programs to bridge gaps between technology capabilities and localized needs, thereby enabling more effective integration into routine care.
A focused industry perspective on how diverse vendor strategies, clinical evidence generation, and strategic partnerships are shaping competitive advantage in biopsy technologies
Competitive dynamics among leading companies are defined by portfolios that blend procedural devices, imaging integration, and post-procedural support services. Market leaders tend to invest heavily in iterative device improvements that enhance tissue yield and operator ergonomics while pursuing partnerships with imaging and digital health vendors to strengthen end-to-end solutions. Mid-sized and emerging firms often concentrate on niche performance differentiators such as single-use convenience, advanced needle metallurgy, or modular guidance systems that reduce training burden. Strategic collaborations between device manufacturers and diagnostic laboratories or pathology service providers are also notable, as they help close the loop between sample acquisition and actionable molecular reporting.
Investment in clinical evidence and training infrastructure remains a core competitive lever; companies that can demonstrate consistent procedural outcomes across multiple institutions enjoy advantages in procurement discussions. Furthermore, service and reimbursement support capabilities are increasingly important, with vendors providing procedural analytics, maintenance programs, and bundled offerings that address total cost of ownership and operational continuity. Intellectual property management and regulatory agility continue to play a role in sustaining differentiation, while active surveillance of regulatory guidance and clinical guideline updates informs product roadmaps and market messaging strategies.
Actionable strategic recommendations for manufacturers, clinical leaders, and procurement teams to drive resilient growth and sustainable clinical impact in biopsy care
Industry leaders should pursue a balanced strategy that aligns product innovation with operational realities and payer expectations. Prioritize investments in technologies that demonstrably improve specimen quality and reduce repeat procedures, while ensuring that device designs accommodate the needs of ambulatory and office-based settings as well as hospitals. Strengthening supplier diversification and contingency inventory policies will mitigate exposure to trade policy shifts and lead-time disruptions. In parallel, cultivate partnerships with imaging platform providers and pathology services to create integrated solutions that streamline pre-procedural planning and post-procedural diagnostic workflows.
Operationalizing these priorities requires enhanced clinician training programs, simulation curricula, and certification pathways to decrease procedural variability and accelerate adoption. Engage payers proactively by generating real-world evidence that links procedural choices to downstream diagnostic accuracy and care utilization. Finally, adopt modular business models that combine capital, disposables, and service contracts to align vendor incentives with provider outcomes and create durable, value-aligned relationships with purchasing stakeholders.
A transparent methodology summary describing evidence sources, expert interviews, triangulation practices, and limitations that underpin the research insights
The research approach combined a structured review of peer-reviewed literature, regulatory filings, clinical guideline updates, proprietary procedural protocols, and targeted qualitative interviews with interventionalists, pathology leaders, procurement specialists, and device engineers. Primary qualitative interviews focused on procedural decision drivers, device performance in real-world settings, training needs, and supplier selection criteria. Secondary research emphasized cross-referencing clinical practice guidelines, device approvals, and publicly available sourcing information to construct a comprehensive view of technology adoption pathways and supply chain dynamics.
Analytical triangulation was applied to reconcile divergent perspectives and validate recurring themes, while sensitivity to regional regulatory and reimbursement differences informed segmentation analyses. Limitations are acknowledged where heterogeneity in clinical reporting or proprietary contracting obscured complete transparency, and such areas were treated conservatively in interpretation. Ethical standards for interview consent and confidentiality were maintained throughout, and findings were synthesized to prioritize actionable insight while preserving methodological rigor and transparency about data provenance.
A concise conclusion synthesizing technological advances, operational shifts, and strategic priorities that will determine long-term biopsy practice evolution
In conclusion, the cancer biopsy landscape is at an inflection point where technological innovation, procedural migration, and supply chain resilience intersect to redefine diagnostic pathways. Improvements in device engineering, integration with advanced imaging, and emphasis on specimen quality are collectively enhancing diagnostic confidence and enabling closer alignment with precision oncology objectives. Simultaneously, evolving care settings and trade policy adjustments are prompting stakeholders to rethink sourcing strategies, training programs, and procurement practices to maintain continuity and optimize clinical outcomes.
Moving forward, the most effective strategies will be those that integrate product innovation with robust clinical evidence generation, targeted education, and adaptive commercial models that reflect venue-of-care differences. Organizations that anticipate regulatory shifts, diversify supply chains, and invest in partnerships across imaging and diagnostic services will be better positioned to deliver sustained value to clinicians, patients, and health systems. The convergence of technological capability and operational insight thus offers a path to more reliable, patient-centered tissue diagnosis and streamlined integration into contemporary oncology care.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
185 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Integration of liquid biopsy assays for early cancer detection using ctDNA and exosomal biomarkers
- 5.2. Adoption of AI-driven image analysis in needle biopsy procedures to enhance diagnostic accuracy and reduce sample processing times
- 5.3. Development of minimally invasive robotic biopsy devices enabling precision sampling of deep-seated tumors
- 5.4. Expansion of next-generation sequencing panels in biopsy specimens to guide personalized oncology treatment decisions
- 5.5. Growth of point-of-care biopsy diagnostic platforms for rapid molecular profiling in outpatient oncology settings
- 5.6. Emergence of multianalyte liquid biopsy tests combining circulating tumor cells, DNA, and RNA for comprehensive tumor characterization
- 5.7. Regulatory approvals and reimbursement reforms driving commercialization of innovative biopsy technologies in major markets
- 5.8. Collaborations between diagnostic companies and academic centers to validate novel biopsy biomarkers and protocols
- 5.9. Rise of pan-cancer early detection assays leveraging cfDNA methylation profiling for multi-cancer screening
- 5.10. Integration of AI-driven decision support tools with biopsy genotyping data to predict patient outcomes and therapy response
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Cancer Biopsy Market, by Product Type
- 8.1. Core Needle Biopsy
- 8.2. Fine Needle Aspiration
- 8.3. Surgical Biopsy
- 8.4. Vacuum-Assisted Biopsy
- 9. Cancer Biopsy Market, by Technology
- 9.1. Imaging Guided Biopsy
- 9.2. Manual Freehand Biopsy
- 9.3. Robotic Assisted Biopsy
- 10. Cancer Biopsy Market, by Application
- 10.1. Breast
- 10.2. Liver
- 10.3. Lung
- 10.4. Prostate
- 10.5. Thyroid
- 11. Cancer Biopsy Market, by End User
- 11.1. Ambulatory Surgical Centers
- 11.2. Diagnostic Imaging Centers
- 11.3. Hospitals
- 11.4. Physicians Offices
- 12. Cancer Biopsy Market, by Region
- 12.1. Americas
- 12.1.1. North America
- 12.1.2. Latin America
- 12.2. Europe, Middle East & Africa
- 12.2.1. Europe
- 12.2.2. Middle East
- 12.2.3. Africa
- 12.3. Asia-Pacific
- 13. Cancer Biopsy Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
- 14. Cancer Biopsy Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
- 15. Competitive Landscape
- 15.1. Market Share Analysis, 2024
- 15.2. FPNV Positioning Matrix, 2024
- 15.3. Competitive Analysis
- 15.3.1. F. Hoffmann-La Roche Ltd.
- 15.3.2. QIAGEN N.V.
- 15.3.3. Illumina, Inc.
- 15.3.4. Thermo Fisher Scientific, Inc.
- 15.3.5. Becton, Dickinson and Company
- 15.3.6. Guardant Health, Inc.
- 15.3.7. Myriad Genetics, Inc.
- 15.3.8. Hologic, Inc.
- 15.3.9. Exact Sciences Corporation
- 15.3.10. Danaher Corporation
- 15.3.11. Bio-Rad Laboratories, Inc.
- 15.3.12. Boston Scientific Corporation
- 15.3.13. Argon Medical Devices, Inc.
- 15.3.14. Natera, Inc.
- 15.3.15. Cardinal Health, Inc.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
